Clinical Performance Evaluation of the NeuMoDx™ FluA/FluB/RSV/Severe Acute Respiratory Syndrome-CoV-2 Assay

CompletedOBSERVATIONAL
Enrollment

2,383

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

February 7, 2024

Study Completion Date

February 7, 2024

Conditions
Respiratory Disease
Interventions
DEVICE

NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay

The NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay (IUO) is a multiplexed, in vitro real-time Polymerase Chain Reaction assay, diagnostic test intended for the simultaneous qualitative detection and differentiation of Influenza A virus (Flu A), Influenza B virus (Flu B), Respiratory Syncytial Virus (RSV) and SARS-CoV-2 RNA

Trial Locations (1)

M130BH

QIAGEN Gaithersburg, Inc, Manchester

All Listed Sponsors
lead

QIAGEN Gaithersburg, Inc

INDUSTRY